Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials

Arthritis Care and Research

Volumn 70, Issue 3, 2018, Pages 439-444

  Namas, Rajaie ^a   Tashkin, Donald P ^b   Furst, Daniel E ^b,c   Wilhalme, Holly ^b   Tseng, Chi Hong ^b   Roth, Michael D ^b   Kafaja, Suzanne ^b   Volkmann, Elizabeth ^b   Clements, Philip J ^b   Khanna, Dinesh ^a   Elashoff, R ^c   Goldin, J ^c   Roth, M ^c   Bulpitt, K ^c   Chung, W L J ^c   Viasco, S ^c   Sterz, M ^c   Woolcock, L ^c   Yan, X ^c   Ho, J ^c   Vasunilashorn, S ^c   da Costa, I ^c   Seibold, J R ^c   Riley, D J ^c   Amorosa, J K ^c   Hsu, V M ^c   McCloskey, D A ^c   Wilson, J E ^c   Varga, J ^c   Schraufnagel, D ^c   Wilbur, A ^c   Lapota, D ^c   Arami, S ^c,c   Cole Saffold, P ^c   Simms, R ^c   Theodore, A ^c   Clarke, P ^c   Korn, J ^c   Tobin, K ^c   Nuite, M ^c   Silver, R ^c   Bolster, M ^c   Strange, C ^c   Schabel, S ^c   Smith, E ^c   Arnold, J ^c   Caldwell, K ^c   Bonner, M ^c   Wise, R ^c   Wigley, F ^c   White, B ^c   Hummers, L ^c,c   Bohlman, M ^c   Polito, A ^c   Leatherman, G ^c,c   Forbes, E ^c   Daniel, M ^c   Martin, D ^c   Steen, V ^c   Read, C ^c   Cooper, C ^c   Wheaton, S ^c   Carey, A ^c   Ortiz, A ^c   Mayes, M ^c,c   Parsley, E ^c   Oldham, S ^c   Filemon, T ^c   Jordan, S ^c   Perry, M ^c,c   Connolly, K ^c   Golden, J ^c   Wolters, P ^c   Webb, R ^c   Davis, J ^c   Antolos, C ^c   Maynetto, C ^c   Fessler, B ^c   Olman, M ^c   Sanders, C ^c   Heck, L ^c   Parkhill, T ^c   Rothfield, N ^c   Metersky, M ^c   Cobb, R ^c   Aberles, M ^c   Ingenito, F ^c   Breen, E ^c   Mubarak, K ^c   Granda, J L ^c   Silva, J ^c   Injic, Z ^c   Alexander, R ^c   Springmeyer, S ^c   Kirkland, S ^c   Molitor, J ^c   Hinke, R ^c   Mondt, A ^c   Thompson, T ^c   Rounds, S ^c   Weinstein, M ^c   Thompson, B ^c   Paulus, H ^c   Levy, S ^c   Kissin, E ^c   Cheong, F Y ^c   Marlis, G ^c   Mason Berry, J ^c   Saffold, P ^c   Rodriguez, M ^c   Guzman, L ^c   Brook, J ^c   Ibrahim, G ^c   Largaespada, K ^c   Fridley, C ^c   Zulmastashvili, M ^c   Manu, A ^c   Moore, S ^c   Hant, F N ^c   Gibson, K ^c   Morrison, M ^c   Donnelly, H ^c   Marlin, C ^c   Gangar, J ^c   Eller, A ^c   Leong, D ^c   Lalosh, M ^c   Obata, J ^c   Franklin, D ^c   Schiopu, E ^c   Benedict Blue, M ^c   Leone, V ^c   Shaw, J ^c   Tan, F ^c   Anderson, J ^c   Saulino, A ^c   Carey, P ^c   Esplin, M ^c   Carlson, P ^c   more..

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; PLACEBO; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; CLINICAL STUDY; DIFFUSE SCLERODERMA; DRUG EFFICACY; HUMAN; MODIFIED RODNAN SKIN SCORE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SKINFOLD THICKNESS; TREATMENT DURATION; TREATMENT RESPONSE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOLOGY; INTERSTITIAL LUNG DISEASE; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MYCOPHENOLIC ACID; REMISSION INDUCTION; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 85041518443     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23282     Document Type: Article

References (19)

1. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60:2490–8.
2. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
3. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630–40.
4. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351–8.
5. Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24-week randomized double-blind trial, followed by a 24-week observational trial. Br J Rheumatol 1996;35:364–72.
6. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.
7. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962–70.
8. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708–19.
9. Domiciano DS, Bonfa E, Borges CT, Kairalla RA, Capelozzi VL, Parra E, et al. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 2011;30:223–9.
10. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002;29:298–304.
11. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006;25:205–12.
12. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology (Oxford) 2007;46:442–5.
13. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011;70:1104–7.
14. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026–34.
15. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65:1325–9.
16. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445–54.
17. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151–7.
18. Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) 2015;54:1944–53.
19. Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685–99.